Risk Factors Update Summary
- Sales of HIV products increased from 64% to 67% of total product sales.
- FDA investigating T-cell malignancies in CAR T-cell therapy patients, impacting safety labeling.
- FDA placed a full clinical hold on magrolimab studies, leading to discontinuation in hematologic cancers.
- Product sales denominated in foreign currencies decreased from 31% to 26%.
- Interest rates and inflation changes may expose the company to increased financial risk.
- Climate change regulations may increase operating costs and affect the company's operations.
- Cybersecurity incidents are increasing, leading to potential financial, legal, and reputational losses.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=882095&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.